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14,000,000  
New cases of cancer in 2012 
8,800,000  
Deaths Worldwide in 2015 
$1.16 trillion  
Spent on cancer healthcare in 2010 in the US 
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What is Cancer? 
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Hallmarks of Cancer 
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Chromosome 
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Nucleosomes 
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Nucleosomes 
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Histone Modifiers 
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Mixed Lineage Leukemia Gene 
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Our Project 2 
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Purpose 
The aim of this project is to inhibit Normal MLL gene 
expression in MCF-7 breast cancer cells by utilizing 
the CRISPR/Cas9 gene editing tool to see if the 
cells can undergo apoptosis.  
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Guiding Question 
Will normal MLL gene knockout in MCF-7 breast 
cancer cells cause the onset of apoptosis? 
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Hypothesis 
By knocking out wildtype MLL, the cells will reverse the 
phenotypes of cancer and die.  
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Materials and Methods 3 
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Outline 
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CRISPR/Cas 9 
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Vector Map 
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MLL-gRNA 
5’ ACCGgACACAGCTCGTTTTCGGCCA 3’ 
             3’ TGTGTCGAGCAAAAGCCGGCAAA 5’ 
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Shen Castan Edge Detection 
Algorithm 
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Results 4 
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P value = 0.0193817 
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P value = 0.0230586 
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P value = 0.0573329 
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P value = 0.0355525 
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Discussion 5 
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◇  Trial 2 shows that CRISPR/Cas 9 worked for the MLL group 
￭  MLL had low numbers of cells 
￭  Control kept growing 
￭  Plasmid kept the same amount of cells 
￮  Didn’t grow nor die 
◇  Other trials did not show the same results 
￭  More trials to confirm results 
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Further Implications 6 
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Implications of the Results 
◇  Future Medical Therapies  
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Future of the Project 




￭ Check the DNA  
◇  Refine the process 
◇  Move on to other types of cancers 
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